CliffBio
small molecule

BUPIVACAINE HYDROCHLORIDE

BUPIVACAINE HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyMeitheal Pharmaceuticals, Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameBUPIVACAINE HYDROCHLORIDE
Active ingredientBUPIVACAINE HYDROCHLORIDE
Strength0.25%
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalJune 2023
Marketing statusRX

More from Meitheal Pharmaceuticals, Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

BUPIVACAINE HYDROCHLORIDE patent cliff — loss of exclusivity — | CliffBio